Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the safety and effectiveness of FLT201, a gene therapy, in adults with Gaucher disease Type 1 who have been on stable enzyme replacement or substrate reduction therapy for at least two years. This Phase 3 study aims to confirm how well FLT201 works and its safety after participants stop their current therapies. Participants will receive a single intravenous infusion of FLT201, which is an advanced gene therapy made from a modified virus vector carrying genetic material. The study is non-randomized and conducted at multiple centers, focusing on this one group receiving the investigational treatment. Throughout the study, participants will be monitored for response to FLT201 over a year to evaluate its effectiveness. Researchers will assess safety and track health outcomes, with the overall study lasting several years. This includes follow-up visits and evaluations to understand long-term impacts of the gene therapy.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and organ dosimetry of two investigational drugs, 177LuLu-A9-0631 and 225AcAc-A9-0642, in adults with Gastrin-Releasing Peptide Receptor GRPR expressing locally advanced, unresectable, or metastatic solid tumors. This Phase 1-1b multicenter study aims to establish safe dosing and explore how these drugs work in patients with breast cancer, prostate cancer, colorectal cancer, and other GRPR-positive tumors. The study is sponsored by Alpha-9 Oncology USA Inc. The study has two parts Phase 1 involves gradually increasing doses of the drugs to find the maximum tolerated dose and recommended dose for later studies. Phase 1b expands to more participants to further assess safety, effectiveness, and dosimetry at the determined dose. The investigational drugs, along with diagnostic tests using 68GaGa-A9-6217 and low dose 177LuLu-A9-0631, are given intravenously. Each treatment cycle lasts 28 days, with up to six cycles possible. Participants will be closely monitored for side effects, treatment responses, and radiation doses absorbed by organs and tumors. Evaluations include scans, imaging, laboratory tests, and safety assessments from the first dose through 30 days after the last dose. Objective response rates and absorbed dose estimates are measured regularly up to 12 months after treatment. The entire study period extends through December 2029, with ongoing safety and efficacy follow-up.
Actively Recruiting
Researchers are evaluating nipocalimab, a drug given intravenously or subcutaneously, for adults with generalized myasthenia gravis gMG, a condition causing muscle weakness. This Phase 3 study aims to compare the effectiveness and safety of nipocalimab against a placebo and to understand how the drug works in the body when given by injection under the skin versus through a vein. The study includes a subcutaneous substudy to explore these differences in delivery methods. Participants receive nipocalimab intravenous infusions every two weeks for up to 24 weeks during a double-blind placebo-controlled phase. Those completing this phase can enter an open-label extension, choosing to continue receiving intravenous nipocalimab or switch to the subcutaneous form given weekly for eight weeks, with the option to continue longer in a long-term extension. Placebo is also given intravenously every two weeks in the control group during the double-blind phase. Throughout the study, participants undergo regular assessments including muscle function scores, quality of life evaluations, and blood tests measuring antibody levels and drug concentration. Researchers monitor safety by tracking adverse events and changes in clinical and laboratory parameters. The study measures changes in activities of daily living related to myasthenia gravis over time. Participation may last several years, as long-term monitoring continues after the initial treatment phases to evaluate ongoing effects and safety.
Actively Recruiting
This research aims to evaluate the safety and potential side effects of the Akyva System, an implantable device designed to electrically stimulate the bladder muscle to improve urination in people with underactive bladder. The study includes both patients with non-neurogenic underactive bladder and those with neurogenic underactive bladder due to spinal cord injury. Researchers want to see if the device helps reduce the need for catheter use and improves urine emptying. Participants will receive the Akyva System device implanted to directly stimulate the bladder wall muscle that controls urination. The study includes patients who currently use intermittent catheterization for urinary retention and are medically able to undergo surgery. The devices safety and surgical feasibility will be assessed from enrollment through up to 18 months after implantation. During the study, participants will be monitored for safety and any side effects following device implantation. Researchers will evaluate how well the device improves bladder emptying over 18 months, including reviewing bladder diary records and clinical assessments. Participants will undergo follow-up visits to track the devices performance and their urinary function throughout the study period, which lasts until September 2028.
Actively Recruiting
Researchers are evaluating the effects of YB-101 on thyroid function in people with Graves Disease. This trial aims to assess how safe and well tolerated YB-101 is, as well as how it is distributed in the body. The study includes two parts a first blinded treatment period and a second double-blinded treatment period, where participants receive either YB-101 or a placebo. Participants receive YB-101 or placebo through subcutaneous injections over a 24-week period. Those in Part 1 will not be eligible to join Part 2. The study involves approximately 34 to 39 visits at the clinic over about 40 weeks, depending on whether participants are in Part 1 or Part 2. Throughout the study, participants will attend many clinic visits to monitor their health and response to the treatment. Researchers will track adverse events and measure thyroid hormone levels including free triiodothyronine, free thyroxine, and thyroid-stimulating hormone. The study will also observe whether participants can stop anti-thyroid drugs regardless of levothyroxine use. Safety, tolerability, and effects on thyroid function will be assessed until about Day 169 of treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ficerafusp alfa combined with pembrolizumab compared to placebo with pembrolizumab in adults with first-line PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma HNSCC. This study targets two cancer drivers, EGFR and TGF-beta, to address tumor growth and spread. It includes phase 2 to find the best dose and phase 3 to compare treatment outcomes. In phase 2, participants are randomly assigned to one of three groups ficerafusp alfa 1500 mg weekly plus pembrolizumab every three weeks, ficerafusp alfa 750 mg weekly plus pembrolizumab every three weeks, or placebo weekly plus pembrolizumab every three weeks. Phase 3 uses the optimal dose of ficerafusp alfa with pembrolizumab versus placebo with pembrolizumab in a 21 ratio. Treatments continue with scheduled dosing during each phase. Participants undergo regular assessments including scans to measure tumor response by RECIST 1.1 criteria, safety monitoring for side effects, and quality of life questionnaires. The study tracks objective response rate, overall survival, progression-free survival, and other measures over up to three years. Safety is closely monitored for treatment-related adverse events during and after therapy. Total participation may last several years depending on treatment and follow-up.
Actively Recruiting
Researchers are evaluating the combination of brenetafusp IMC-F106C plus nivolumab compared to standard nivolumab regimens in people with previously untreated advanced melanoma who are HLA-A*0201-positive. This phase 3, randomized, controlled study aims to understand how these treatments perform in this specific group. The study focuses on improving progression-free survival and overall outcomes for participants with advanced melanoma. Participants are assigned to one of three groups one group receives a low dose of brenetafusp once weekly for 13 weeks, then every two weeks until Week 51, and every four weeks thereafter, along with nivolumab every four weeks another group receives a high dose of brenetafusp on the same schedule plus nivolumab the third group receives nivolumab alone or nivolumab combined with relatlimab every four weeks. The study includes a dose recommendation phase with changes made in November 2025 based on safety and efficacy data. During the study, participants undergo assessments including tumor measurements per RECIST 1.1, BRAF V600 mutation status evaluation, and performance status scoring. Researchers will monitor progression-free survival up to approximately 45 months, overall survival up to 57 months, and record adverse events, immune responses, and quality of life. The study involves regular dosing and long-term follow-up to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of 177Lu-TLX250, a targeted radioligand therapy, in adults with advanced, relapsed, or recurrent clear cell renal cell carcinoma ccRCC that expresses the CAIX protein. This Phase 3, randomized, open-label study aims to find the best dosing regimen and compare 177Lu-TLX250 to standard single-agent therapies used in Australia. The study includes participants who have previously received multiple systemic treatments and have measurable disease progression. The study has two parts Part 1 focuses on dose optimization by randomly assigning participants to receive either three infusions of 177Lu-TLX250 at 8-week intervals or six infusions at 4-week intervals. Part 2 compares the chosen dose of 177Lu-TLX250 with the investigators choice of a single standard therapy. Treatments are given intravenously, and the study evaluates different dosing schedules over several months. Participants will undergo various assessments including imaging scans, laboratory tests, and quality of life questionnaires throughout the study, which lasts about two years. Researchers will monitor safety, treatment response, survival, and how the drug distributes in the body. They will also evaluate side effects, immune responses, and radiation exposure. This comprehensive monitoring helps understand the therapys impact and tolerability over time.
Actively Recruiting
Researchers are conducting a Phase 1 study to evaluate STM-416p, a drug administered during surgery to patients with prostate cancer undergoing radical prostatectomy. This early phase trial focuses on determining the safety and tolerability of STM-416p in this patient population, particularly monitoring dose-limiting toxicities and adverse events up to 90 days after treatment. During the trial, STM-416p will be given intraoperatively as a monotherapy to patients scheduled for radical prostatectomy. The study involves escalating doses to find a safe and tolerable dose. Researchers will also study how the drug moves through and affects the body by measuring pharmacokinetics and pharmacodynamics at various time points after administration. Additionally, surgical wound healing will be assessed on days 7 and 21 post-surgery. Participants will be closely monitored throughout the trial with safety assessments focusing on adverse events and wound healing. Blood samples will be collected to analyze drug levels and immune responses. The total observation period includes safety follow-up up to 90 days post-treatment. Male participants aged 18 and older diagnosed with prostate cancer and eligible for radical prostatectomy will be involved, with detailed evaluations to ensure organ function and performance status meet study requirements.
Actively Recruiting
Researchers are evaluating a treatment for adults with unresectable, locally advanced, or metastatic HER2-positive gastric or gastroesophageal junction GEJ cancer. The study compares the effectiveness and safety of a combination including trastuzumab deruxtecan T-DXd plus a fluoropyrimidine and pembrolizumab versus the current standard chemotherapy plus trastuzumab and pembrolizumab. The study includes a main group with PD-L1 CPS score 1 or higher and an exploratory group with PD-L1 CPS less than 1, aiming to improve first-line therapy options. Participants will be randomly assigned to one of four treatment groups the main group receives either T-DXd with fluoropyrimidine plus pembrolizumab or trastuzumab with platinum-based chemotherapy plus pembrolizumab the exploratory group receives either T-DXd with fluoropyrimidine or trastuzumab with platinum-based chemotherapy. T-DXd and pembrolizumab are given intravenously every three weeks, while chemotherapy varies between 5-FU, capecitabine, cisplatin, or oxaliplatin combinations. The study evaluates these regimens over the course of treatment to assess their impact on cancer progression. During the study, participants will have tumor samples collected to confirm HER2 and PD-L1 status and undergo imaging scans to measure tumor lesions. Heart function and lung health will be monitored to ensure safety. Researchers will assess progression-free survival and overall survival up to 59 months after randomization. Participants are expected to attend regular visits for treatment administration and safety evaluations over the treatment period and follow-up assessments according to the study schedule.